Abstract
SARS-CoV-2 causes a spectrum of COVID-19 disease, the immunological basis of which remains ill defined. We analyzed 85 SARS-CoV-2-infected individuals at acute and/or convalescent time points, up to 102 days after symptom onset, quantifying 184 immunological parameters. Acute COVID-19 presented with high levels of IL-6, IL-18, and IL-10 and broad activation marked by the upregulation of CD38 on innate and adaptive lymphocytes and myeloid cells. Importantly, activated CXCR3+cTFH1 cells in acute COVID-19 significantly correlate with and predict antibody levels and their avidity at convalescence as well as acute neutralization activity. Strikingly, intensive care unit (ICU) patients with severe COVID-19 display higher levels of soluble IL-6, IL-6R, and IL-18, and hyperactivation of innate, adaptive, and myeloid compartments than patients with moderate disease. Our analyses provide a comprehensive map of longitudinal immunological responses in COVID-19 patients and integrate key cellular pathways of complex immune networks underpinning severe COVID-19, providing important insights into potential biomarkers and immunotherapies. Koutsakos et al. perform a broad analysis of 184 immune features using blood samples from 85 COVID-19 cases across time and severity groups. The study defines circulating TFH1 cells as a correlate of antibody responses and sIL-6R, IL-6, and IL-18 as correlates of disease severity.
Original language | English |
---|---|
Article number | 100208 |
Pages (from-to) | 1-22 |
Number of pages | 22 |
Journal | Cell Reports Medicine |
Volume | 2 |
Issue number | 3 |
DOIs | |
Publication status | Published - 4 Feb 2021 |